Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed breast cancer~  * Disease must be confined to the breast and axillary nodes without detected masses elsewhere~ * No history of prior ipsilateral or contralateral invasive breast cancer~* Resected disease~  * No more than 16 weeks since last surgery to remove the tumor~ * No known clinical residual locoregional disease~ * Margins must be negative for invasive breast cancer and ductal carcinoma in situ~* No locally advanced, inoperable breast cancer including any of the following:~  * Inflammatory breast cancer~ * Supraclavicular node involvement~ * Enlarged internal mammary nodes unless pathologically negative~* Synchronous bilateral invasive breast cancer (diagnosed in the past 2 months) allowed if all tumors are hormone receptor-negative~* Must not be a candidate for endocrine therapy or standard chemotherapy~* Hormone receptor-negative disease~PATIENT CHARACTERISTICS:~* Female~* Menopausal status: postmenopausal~* ECOG performance status 0-2~* Platelet count ≥ 100,000/mm\^3~* Granulocyte count ≥ 1,500/mm\^3~* WBC ≥ 3,000/mm\^3~* AST and ALT ≤ 1.5 times upper limit of normal (ULN)~* Bilirubin normal~* Creatinine clearance ≥ 50 mL/min~* Creatinine \< 1.35 mg/dL~* No significant malabsorption syndrome or disease affecting gastrointestinal tract function~* No myocardial infarction within the past 6 months~* No pulmonary embolism within the past 6 months~* No deep vein thrombosis within the past 6 months~* No New York Heart Association class III or IV heart disease~* LVEF ≥ 50% by echocardiography, radionucleotide ventriculography, or MUGA~* No evidence of acute ischemia by ECG~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or bladder, or ipsilateral or contralateral breast carcinoma in situ~* No active, uncontrolled infection~* No active hepatitis B or C virus infection~* No other chronic infection~* Patients must not have any of the following geriatric syndromes:~  * Dementia~ * Delirium~ * Major depression (as diagnosed by a psychiatrist)~ * Recent falls~ * Spontaneous bone fractures~ * Neglect~ * Abuse~* No evidence of medically relevant conduction system abnormalities that would preclude study entry~* No other nonmalignant, uncontrolled systemic diseases, psychiatric illness, or addictive or cognitive disorder that would preclude study participation or compliance~PRIOR CONCURRENT THERAPY:~* At least 4 weeks since prior raloxifene, tamoxifen citrate, or other selective estrogen receptor modulators (SERMs)~* No concurrent recombinant human epoetin alfa or pegfilgrastim~* No prior neoadjuvant or adjuvant therapy for breast cancer except radiotherapy~* Concurrent trastuzumab (Herceptin®) allowed~* No concurrent hormonal replacement therapy~* No other concurrent hormonal therapy (including estrogen, progesterone, androgens, tamoxifen citrate, SERMs, or aromatase inhibitors) except for the following:~  * Steroids for adrenal failure~ * Hormones for non-disease-related conditions (e.g., insulin for diabetes)~ * Intermittent dexamethasone as an antiemetic~* No other concurrent investigational agents~* No concurrent bisphosphonates, except for the treatment of osteoporosis~* For patients who received prior anthracyclines, the following criteria must be met:~  * Cumulative dose ≤ 240 mg/m² for conventional doxorubicin~    * ≤ 140 mg/m² in case of prior doxorubicin and left chest radiotherapy (LCRT)~ * Cumulative dose ≤ 400 mg/m² for epirubicin~    * ≤ 230 mg/m² in case of prior epirubicin and LCRT

- Gender: FEMALE
- Minimum Age: 66 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- CASA-nil PLD (Type: EXPERIMENTAL): Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
- CASA-Nil (Type: ACTIVE_COMPARATOR): No adjuvant therapy
- CASA-CM PLD (Type: EXPERIMENTAL): Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
- CASA-CM CM (Type: ACTIVE_COMPARATOR): Low-dose, metronomic cyclophosphamide and methotrexate (CM) for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues